ZTS Stock Analysis: Buy, Sell, or Hold?
ZTS - ZOETIS INC.
$77.17
-0.56 (-0.72%)
▼
5d:
+5.76%
30d:
+2.42%
90d:
-5.1%
WAIT
LOW Confidence
Analysis Updated: Aug 24, 2026 12:00 AM ET
Earnings: Aug 06, 2026
0d
Smart Money Accumulation
Options open interest is building while the stock consolidates - a pattern consistent with institutional accumulation. View Scanner →
Signal fired Aug 7, 2026 at $72.66 · last confirmed Aug 19, 2026
Strength: 7.3/10
Get Alerted When ZTS Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 MIXED SIGNALS: ZTS shows conflicting indicators. Wait for confirmation before entering.
📊 MIXED SIGNALS: ZTS shows conflicting indicators. Wait for confirmation before entering.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$123.35
Based on 5.2% avg growth
INTRINSIC VALUE TODAY
$76.59
Trading above historical range
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 14.4x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: ZTS is currently trading at $77.17, which is considered extended relative to its 30-day fair value range of $74.20 to $77.17. From a valuation perspective, the stock is trading at a discount (Forward PE: 11.6) compared to its historical average (14.4). Remarkably, the market is currently pricing in an annual earnings decline of 7.0% over the next few years. This pessimistic expectation contrasts with the company's recent 1.2% earnings growth, suggesting potential undervaluation if the company simply maintains stability.
Technical Outlook: Technically, ZTS is in a strong downtrend. The price is approaching resistance at $78.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ZTS scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $100.62 (+30.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, ZTS is in a strong downtrend. The price is approaching resistance at $78.59. A breakout above this level would be a bullish signal, while rejection here could lead to consolidation.
Market Sentiment: ZTS scores 65/100 on our bottoming-setup gauge — the chart has corrected and is stabilizing (RSI reset, momentum turning up), historically a favorable entry zone. Wall Street analysts see significant upside, with an average price target of $100.62 (+30.4%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
EXTENDED
Historical Trading Range
$74.20 -
$77.17
Company Quality Score
50/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
61.9%
Protect Your Profits
Holding ZTS? Use our AI-powered strategies to protect your downside while keeping your long-term position.
View Profit Protection PlanAll Signals
- BEARISH: Price extended above range
- BULLISH: Strong technical setup (65/100)
- BULLISH: High volume confirmation
- BULLISH: Trading 30.4% below Wall St target ($100.62)
- WARNING: Composite score 50/100 in the bottom quintile — this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$74.20 -
$77.17
Current vs Trading Range
EXTENDED
Support & Resistance Levels
Support Level
$71.00
Resistance Level
$78.59
Current Trend
Strong Downtrend
Technical data as of
Aug 24, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.61
Wall Street Target
$100.63
(+30.4%)
Revenue Growth (YoY)
-0.2%
Earnings Growth (YoY)
1.2%
Profit Margin
27.7%
Valuation Discount vs History
-7.0% cheaper
PE vs Historical
11.6 vs 14.4
CHEAP
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
-7.0%
(market-implied from PE analysis)
1-Year Target
$71.77
(-7%)
2-Year Target
$66.74
(-14%)
3-Year Target
$62.07
(-20%)
3-Yr Target (if PE normalizes)
(PE: 12→14)
$77.01
(0%)
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 20.1, Growth: 6.4%)
$160.54
(+108%)
Base:
(SPY PE: 11.6, Growth: 6.4%)
$92.93
(+20%)
Bear:
(PE: 9.9, Growth: 6.4%)
$78.99
(+2%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (13x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 12.68 | Current EPS (TTM): $6.13
Bull Case
$92.74
(+20%)
Analyst growth 8.5%, PE expands to 14.0
Base Case
$84.31
(+9%)
Market implied 8.5%, PE stable at 12.7
Bear Case
$52.86
(-32%)
Severe decline -20.0%, PE contracts to 10.8
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
💡
Upside Surprise Potential
If earnings stabilize (0% growth), PE could expand from 11.6 to 14.4
Stabilization Target:
$95.75
(+24.1%)
PE Expansion Potential:
+24.1%
Share & Embed Analysis
Last updated: August 25, 2026 9:20 AM ET
Data refreshes hourly during market hours. Next update: 10:20 AM
Data refreshes hourly during market hours. Next update: 10:20 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is ZTS showing a specific setup today?
Insider Activity (6 Months)
0
Buys
3
Sells
Net
INSIDERS SELLING
Recent Transactions
Ro Khanna
SELL
2026-03-30
Ro Khanna
SELL
2026-03-23
Gilbert Ray Cisneros, Jr.
SELL
2026-03-13
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$212 | 67 BUY |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$107 | 54 HOLD |
|
UTHR
United Therapeutics Corp… |
STRONG BUY
15 analysts |
$664 | 49 HOLD |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$21 | 50 HOLD |
|
LQDA
Liquidia Technologies Inc |
STRONG BUY
10 analysts |
$108 | 59 HOLD |
Advanced ZTS Option Strategies
Professional options setups generated by AI based on today's ZTS price and gamma walls.
